Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.45 |
| ▸ | C3AR1 | Q16581 | 3/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CTSG | P08311 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.36 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CD38 | P28907 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7790264 | 1.00 | FOLH1 (0.45) | FOLH1C3AR1TGM2SMN1; SMN2NPSR1 | |
| SCHEMBL7788448 | 0.90 | C3AR1 (0.44) | FOLH1C3AR1ITGB1ITGA5 | |
| SCHEMBL7788437 | 0.90 | C3AR1 (0.44) | FOLH1C3AR1ITGB1ITGA5 | |
| SCHEMBL7788436 | 0.85 | FOLH1 (0.56) | FOLH1C3AR1TGM2 | |
| SCHEMBL7788471 | 0.83 | FOLH1 (0.57) | FOLH1C3AR1 | |
| SCHEMBL7788481 | 0.83 | FOLH1 (0.57) | FOLH1C3AR1 | |
| SCHEMBL7786368 | 0.82 | FOLH1 (0.49) | FOLH1C3AR1SMN1; SMN2 | |
| SCHEMBL7786354 | 0.82 | FOLH1 (0.49) | FOLH1C3AR1SMN1; SMN2 | |
| SCHEMBL7786351 | 0.82 | FOLH1 (0.43) | FOLH1C3AR1 | |
| SCHEMBL7786343 | 0.82 | FOLH1 (0.43) | FOLH1C3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010056185-A1 | C3A receptor ligands | LEE DENNIS (US) | 2001-12-27 | — | — | US | disclosed |
| EP-1017664-A1 | C3A RECEPTOR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999015490-A1 | C3A RECEPTOR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056185-A1 | C3A receptor ligands | C3AR1, C5AR1, C5AR2 | FOLH1 1373/4885C3AR1 1/4885TGM2 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.